What are the generic drugs of Gilteritinib?

Gilitinib is a highly selective FLT3 tyrosine kinase inhibitor, mainly used to treat relapsed or refractory patients with FLT3 gene mutations in acute myeloid leukemia (AML). FLT3 gene mutation is an important molecular marker for poor prognosis in AML patients. The use of giritinib can target this driving pathway, inhibit leukemia cell proliferation and promote disease control. Giritinib is convenient for oral administration and has strong drug targeting. At the same time, compared with traditional chemotherapy, it has relatively less inhibition on the normal hematopoietic system, improving the patient's quality of life.

In addition to the original drug being launched in many overseas countries, generic drugs of gilitinib are currently on the market. Generic drugs are basically the same as the original drugs in terms of drug ingredients, but there may be differences in manufacturers, packaging specifications and prices. Common generic drug manufacturers include Laos Lucius Pharmaceuticals, Daxiong Pharmaceutical Factory, etc. Most of the specifications are 40mg*84 tablets. The price per box is about more than 2,000 yuan. The price may change due to exchange rate fluctuations. These generic drugs provide patients with more flexible dosing options while reducing treatment costs.

In clinical use, giritinib is suitable for adult patients with relapsed or refractory AML with positive FLT3 mutation. Before treatment, the FLT3 gene mutation status needs to be clarified, and an individualized dose and monitoring plan should be developed based on the patient's previous chemotherapy regimen, hematological indicators and overall health status. During the treatment process, patients need to undergo regular hematology and biochemical tests to monitor platelets, white blood cells, liver and kidney functions, and promptly detect potential side effects, such as bone marrow suppression or elevated liver enzymes, to ensure the safety of treatment.

Overall, giritinib, as an important targeted drug in the treatment of AML, provides an effective treatment option for patients with FLT3 mutation-positive patients. With the introduction of generic drugs, patient access and affordability have improved.

Reference materials:https://www.xospata.com/